Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China

References

• Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717.
   PubMed Web of Science ®Google Scholar
• The Global Cancer Observatory. China face sheet. Globanacan; 2020 [cited 2020 Oct 12]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf
   Google Scholar
• Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6(1):77.
   PubMedGoogle Scholar
• Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839–1845.
   PubMed Web of Science ®Google Scholar
• Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31(25):3100–3109.
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–1976.
   PubMed Web of Science ®Google Scholar
• Fanin R, Ruiz De Elvira MC, Sperotto A, et al. Autologous stem cell transplantation for T and null cell CD30-Positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). 1999;23:437–442.
   Google Scholar
• Takeda. RRcHL & RRsALCL expert’s survey; 2019.
   Google Scholar
• Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–637.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 2.2015 peripheral T-cell lymphomas; 2015 [cited 2020 Jan 14]. Available from: https://www2.tri-kobe.org/nccn/guideline/hematologic/nhl/english/tcel.pdf
   Google Scholar
• NICE. Technology appraisal guidance [TA478]: brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma; 2017.
   Google Scholar
• d'Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v108–v115.
   PubMed Web of Science ®Google Scholar
• Liu G, Hu S, Wu J, Wu J, Dong Z, Li H, eds. China guidelines for pharmacoeconomic evaluations. 2020th ed. Beijing: China Pharmaceutical Association; 2020.
   Google Scholar
• Lambert PC, Thompson JR, Weston CL, et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007;8(3):576–594.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Oncol Targets Ther. 2014;7:2097–2100.
   Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169–1176.
   PubMed Web of Science ®Google Scholar
• Dong M, He XH, Liu P, et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol. 2013;30(1):351.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(Suppl 1):i5–i10.
   PubMed Web of Science ®Google Scholar
• Yaozh website [cited 2020 Jan 14]. Available from: https://www.yaozh.com/
   Google Scholar
• Pricentric [cited 2020 Jan 14]. Available from: https://pricentric.alscg.com/alspc
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections; 2016 [cited 2020 Jan 14]. Available from: https://jnccn.org/view/journals/jnccn/14/7/article-p882.xml?ArticleBodyColorStyles=Inline%20PDF
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: antiemesis; 2016 [cited 2020 Jan 14]. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL; https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
   Google Scholar
• Beijing Social Security Network [cited 2020 Jan 28]. Available from: https://m.chashebao.com/beijing/yiliao/17287.html
   Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D; 1999.
   Google Scholar
• National Bureau of Statistics of China. China statistic yearbook 2020 [cited 2020 Jun 28]. Available from: http://www.stats.gov.cn/tjsj/ndsj/2020/indexch.htm
   Google Scholar
• Hux M, Zou D, Ma E, et al. A cost-effectiveness analysis of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma. JHEOR. 2016;4(2):188–203.
   Google Scholar
• Zou D, Kendall R, Lin Q, et al. Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma in Taiwan. Value in Health. 2016;19(7):A811.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Brentuximab vedotin in Chinese participants with relapsed/refractory CD30-positive hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [cited 2021 Jun 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02939014
   Google Scholar
• Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York: University Press; 1987.
   Google Scholar
• Ellin F, Landstr¨Om J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124(10):1570–1577.
   PubMed Web of Science ®Google Scholar
• Guidelines of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology: lymphoid malignancies 2021. Beijing: People’s Republic Publisher; 2014.
   Google Scholar
• Feldman T, Zou D, Rebeira M, et al. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020;26(2):e41–e49.
   PubMed Web of Science ®Google Scholar
• Roth J, Carlson J, Ramsey S. Cost-Effectiveness assessment of brentuximab vedotin to prevent progression following autologous stem cell transplant in Hodgkin lymphoma in the United States. Blood. 2014;124(21):2657–2657.
   PubMed Web of Science ®Google Scholar
• Hui L, von Keudell G, Wang R, et al. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763–3771.
   PubMed Web of Science ®Google Scholar
• Delea TE, Sharma A, Grossman A, et al. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ. 2019;22(2):117–130.
   PubMed Web of Science ®Google Scholar
• Huntington SF, von Keudell G, Davidoff AJ, et al. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma. J Clin Oncol. 2018;36(33):3307–3314.
   Web of Science ®Google Scholar
• Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282(15):1453–1457.
   PubMed Web of Science ®Google Scholar